Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481004 | 1.00 | CACNA1B (0.59) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL16286010 | 1.00 | CACNA1B (0.59) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL4370045 | 0.94 | KLK5 (0.65) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL19104158 | 0.92 | CACNA1B (0.53) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL23279561 | 0.91 | CACNA1B (0.52) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL25492097 | 0.91 | REN (0.56) | CACNA1BKLK5KLK7REN | |
| SCHEMBL5419241 | 0.90 | KLK7 (0.59) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL25491606 | 0.90 | KLK7 (0.59) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL5870038 | 0.90 | KLK5 (0.64) | CACNA1BKLK5KLK7PPARASYK | |
| SCHEMBL14300984 | 0.90 | KLK5 (0.64) | CACNA1BKLK5KLK7PPARASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-19 | — | — | US | disclosed |
| CN-110573499-A | inhibitors of α v β 6 integrin | 莫菲克医疗股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2018-08-30 | — | — | US | disclosed |
| EP-2751124-B1 | VERSATILE AND STEREOSPECIFIC SYNTHESIS OF GAMMA,DELTA -UNSATURATED AMINO ACIDS BY WITTIG REACTION | CENTRE NAT RECH SCIENT (FR) | 2018-05-16 | — | — | EP | disclosed |
| CN-107835818-A | Anthelmintic depsipeptide compounds | 梅里亚股份有限公司 | 2018-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CACNA1B 213/4885KLK5 2204/4885KLK7 1767/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CACNA1B 213/4885KLK5 2204/4885KLK7 1767/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | CACNA1B 266/4885KLK5 2261/4885KLK7 1555/4885 |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGAV, ITGA6 | CACNA1B 132/4885KLK5 2736/4885KLK7 2111/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CACNA1B 241/4885KLK5 2193/4885KLK7 1791/4885 |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CACNA1B 213/4885KLK5 2204/4885KLK7 1767/4885 |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CACNA1B 213/4885KLK5 2204/4885KLK7 1767/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | CACNA1B 213/4885KLK5 2204/4885KLK7 1767/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CACNA1B 241/4885KLK5 2193/4885KLK7 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.